Two patients with CsA-associated neurotoxicity developed severe cerebellar swelling and thrombotic thrombocytopenic purpura after switching to FK506 and high-dose corticosteroids. The prodrome of CsAassociated neurotoxicity, TTP and hypertension while receiving FK506, and high-dose corticosteroids could all be implicated in the development of this syndrome. Close monitoring of patients receiving FK506 and highdose corticosteroids, for the development of TTP is warranted. Early radiological examination should also be considered in such patients to allow early surgical intervention. Keywords: cerebellar swelling; TTP; FK506; cyclosporine neurotoxicity; steroids Common side-effects of cyclosporin A (CsA) include renal dysfunction, hypertension and tremors.
Treatment of CsA neurotoxicity consists of discontinuing the drug, correcting electrolyte abnormalities and controlling hypertension. 3, 13, 15 Neurologic changes typically resolve within 48 h of discontinuing CsA. In contrast, patients with TTP have a much poorer outcome despite discontinuing CsA, often requiring intensive support. 14 Although ideal management is unclear, it appears that plasma exchange alone 16 or combined with protein immunoadsorption may be effective modes of therapy. 17 The etiology of these disorders is not clear. Cyclosporine is implicated in over 90% of cases of post-BMT TTP. CsA has been shown to cause direct vascular endothelial damage Correspondence: Dr H Tezcan, North Idaho Cancer Center, 700 Ironwood Drive, Coeur d'Alene, ID 83814, USA Received 18 July 1997; accepted 13 August 1997 and to alter the ratio of thromboxane to prostacyclin production resulting in procoagulant activity. [18] [19] [20] [21] [22] [23] [24] Since patients who develop neurologic symptoms attributable to CsA without microangiopathic changes and those who develop TTP are frequently early post-transplant, discontinuing CsA may be associated with development of severe GVHD. The introduction of FK506 into clinical use has allowed substitution of FK506 for CsA in patients developing TTP following BMT and solid organ transplantation. 25 However, the safety of this approach is not well established as there are now reports of FK506-induced TTP following BMT and solid organ transplantation.
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Case 1
A 28-year-old male with Hodgkin's disease received an HLA-matched unrelated donor BMT 2 years after relapsing following an autologous BMT. Conditioning was with thiotepa and carboplatin. He received low-dose intravenous heparin as hepatic veno-occlusive disease (VOD) prophylaxis. GVHD prophylaxis consisted of cyclosporine, methotrexate and methylprednisolone. On day +8, he developed hyperbilirubinemia (primarily direct), associated with an elevated CsA level of 514 (normal range, 250-450). CsA was held and restarted at one-third the previous dose on day +10. On day +11, he developed cortical blindness. The CsA level was within the therapeutic range (395) and renal function and LDH were normal; there were no signs of hemolysis or microangiopathic changes on the blood film. CsA and heparin were discontinued and he was started on FK506. On day +12, an MRI scan showed bioccipital and biparietal T 1 hypointense T 2 hyperintense signal abnormalities, with associated cortical swelling and sulcal effacement ( Figure 1 ). Within 3 days of discontinuation of CsA the visual changes had resolved completely. On day +23, he developed biopsy-proven grade 2 acute GVHD of the skin and gastrointestinal tract. Methylprednisolone was increased to 10 mg/kg q 12 h. On day +28, his LDH increased to 225 IU (upper normal, 185 IU). There were microangiopathic changes (Ͼ5%) on the blood film. MRI showed partial resolution of the occipital/parietal abnormalities; no new abnormalities were identified. On day +31, he became acutely somnolent, progressing to coma within 6 h. MRI showed diffuse swelling with ascending transtentorial and tonsillar herniation. The fourth ventricle was effaced with associated hydrocephalus. The previously identified cortical abnormalities had increased, with new signal abnormalities in the posterior temporal and frontal lobes, as well as the pons, midbrain and thalami. New diffuse patchy enhancement was noted post-gadolinium ( Figure 2 ). By this time, the LDH had risen to 857 IU and the peripheral blood showed moderate to severe (Ͼ5%) schistocytes. There was no evidence of renal dysfunction and electrolytes were normal. Blood pressure which had been well controlled prior to this event was elevated (systolic max 180, diastolic max 110). Support was withdrawn and he died on day +33.
Case 2
A 19-year-old female with acute lymphoblastic leukemia in second CR received an HLA-matched unrelated donor transplant. Conditioning was with etoposide, cyclophos- phamide and total body radiation. She received low-dose intravenous heparin for hepatic VOD prophylaxis. GVHD prophylaxis consisted of CsA, methotrexate and methylprednisolone. On day +15, she developed cortical blindness. Her CsA level was in the therapeutic range (432). The LDH was moderately elevated (234 IU), and the blood smear did not show microangiopathic changes. CsA was discontinued. MRI showed bitemporal/occipital T 1 hypointense T 2 hyperintense signal abnormalities with associated cortical swelling and cortical enhancement after gadolinium administration (Figure 3) . On day +18, she was started on FK506. The LDH rose to 1063 IU. The blood smear continued to show only mild to moderate (Ͻ5%) schistocytes. The rise in LDH was attributed to hemolysis of donor red cells by residual isoagglutinins of the recipient. Visual symptoms improved to baseline, and there were no renal or neurologic abnormalities. On day +22, an upper gastrointestinal endoscopy was carried out which showed severe esophagitis and gastritis. She developed severe watery diarrhea and received high-dose methylprednisolone (10 mg/kg q 12 h) on day +23 to treat presumed enteric GVHD. On day +24, she became hypertensive and somnolent. An emergency CT scan showed diffuse cerebellar edema with ascending transtentorial and tonsillar herniation and associated obstructive hydrocephalus (Figure 4 ). She underwent emergency posterior fossa craniotomy for decompression and an external ventriculostomy, which initially stabilized her neurological status. At this time, she demonstrated many schistocytes (Ͼ5%), a rising LDH (1900 IU) and renal dysfunction (creatinine, 1.8). FK506 was discontinued and plasma-exchange begun. She developed progressive renal and neurologic failure. A repeat CT scan demonstrated new cerebellar and ventricular hemorrhage with brainstem compression. Support was withdrawn, and the patient expired on day +33. Autopsy findings were extensive edema of the cerebellum without microthombotic pathology and hyaline thrombosis of the renal glomeruli consistent with TTP.
Discussion
Both patients developed occipital blindness while receiving CsA. There were no RBC changes consistent with TTP. Symptoms resolved within 48 h of CsA discontinuation. Next, while receiving FK506 they developed GVHD requiring high-dose steroids and TTP. Finally, both developed cerebellar edema and herniation.
In most cases of post-transplant TTP or CsA-associated neurotoxicity, lesions seen on CT scan or MRI are found in the posterior cerebrum and cerebellum. 15, 29, 30 This contrasts with our cases who had cerebellar tonsillar herniation. One possibility is that hypertensive encephalopathy is responsible for the clinical syndrome described. Renal failure associated with TTP, along with the use of FK506 and steroids may contribute to its development. In acute hypertensive events, the posterior circulation unlike the anterior circulation is unable to respond via sympathetic autoregulation with vasoconstriction, and thus, posterior cerebral and cerebellar edema is more prone to develop. 31 The mechanism of CsA-or FK506-associated hypertension is thought to be the result of activation of the sympathetic nervous system. 32, 33 This may direct the blood flow to the posterior regions of the brain, predisposing to hypertensive encephalopathy. 15 In support of this hypothesis is the similarity of CT and MRI changes in patients with CsAassociated neurotoxicity to those seen in hypertensive encephalopathy. 15, 34 In most reported cases of CsA neurotoxicity, hypertension is present during the CNS event. 4, 5, 15, 34 Both of our patients were hypertensive prior to developing cerebellar edema following the addition of high-dose steroids to treat GVHD.
One case in the literature describes a similar clinical course of cerebellar edema and brain stem compression in a patient receiving CsA after a lung transplant. 35 No details were given as to whether this patient had TTP.
High-dose steroids should be used with caution in patients with evidence of TTP who are receiving FK506, and control of hypertension is essential. Early recognition of this uncommon syndrome may be essential in allowing early intervention with potential therapeutic maneuvers such as surgical decompression.
